Related Experiment Videos
Antithrombotic therapy in valvular heart disease
1St. Joseph Mercy-Oakland Hospital, Pontiac, Michigan, USA. steinp@trinity-health.org
Clinics in Geriatric Medicine
|March 29, 2001
Summary
Elderly patients often have an exaggerated response to warfarin therapy, increasing bleeding risks. This review covers antithrombotic strategies for valvular heart disease, considering age-related differences.
Area of Science:
- Cardiology
- Geriatrics
- Pharmacology
Background:
- Antithrombotic therapy is crucial for valvular heart disease.
- Age influences drug response and bleeding risk.
- Warfarin response is notably exaggerated in the elderly.
Purpose of the Study:
- To review antithrombotic therapies for valvular heart disease.
- To address age-related differences in antithrombotic management.
- To discuss specific valve types and therapeutic combinations.
Main Methods:
- Literature review of antithrombotic therapies.
- Analysis of age-related differences in anticoagulation.
- Discussion of various prosthetic valve types and treatment strategies.
Main Results:
- Warfarin response is significantly exaggerated in elderly patients.
- Bleeding risk in the elderly necessitates careful antithrombotic management.
- Specific considerations exist for different prosthetic valves and drug combinations.
Conclusions:
- Antithrombotic therapy requires age-specific adjustments, particularly with warfarin.
- Management strategies must account for valve type, patient age, and bleeding risk.
- Further research may refine antithrombotic protocols for elderly patients with valvular heart disease.